Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer

Patricia Sheean; Sandra Gomez-Perez; Cara Joyce; Paula O’Connor; Monica Bojko; Amber Smith; Vasilios Vasilopoulos; Ruta Rao; Joy Sclamberg; Patricia Robinson

doi:10.1007/s10549-021-06358-6

Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer

Patricia Sheean, Sandra Gomez-Perez, Cara Joyce, Paula O’Connor, Monica Bojko, Amber Smith, Vasilios Vasilopoulos, Ruta Rao, Joy Sclamberg, Patricia Robinson

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	121-132
Number of pages	12
Journal	Breast Cancer Research and Treatment
Volume	190
Issue number	1
DOIs	https://doi.org/10.1007/s10549-021-06358-6
State	Published - Nov 2021
Externally published	Yes

ASJC Scopus Subject Areas

Oncology
Cancer Research

Keywords

Epidemiology
Metastatic breast cancer
Myosteatosis
Sarcopenia
Skeletal muscle

Access to Document

10.1007/s10549-021-06358-6

Cite this

Sheean, P., Gomez-Perez, S., Joyce, C., O’Connor, P., Bojko, M., Smith, A., Vasilopoulos, V., Rao, R., Sclamberg, J., & Robinson, P. (2021). Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer. Breast Cancer Research and Treatment, 190(1), 121-132. https://doi.org/10.1007/s10549-021-06358-6

Sheean, P, Gomez-Perez, S, Joyce, C, O’Connor, P, Bojko, M, Smith, A, Vasilopoulos, V, Rao, R, Sclamberg, J & Robinson, P 2021, 'Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer', Breast Cancer Research and Treatment, vol. 190, no. 1, pp. 121-132. https://doi.org/10.1007/s10549-021-06358-6

@article{8cd2c668db4a4271b57f45c69ff6df1b,

title = "Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer",

keywords = "Epidemiology, Metastatic breast cancer, Myosteatosis, Sarcopenia, Skeletal muscle",

author = "Patricia Sheean and Sandra Gomez-Perez and Cara Joyce and Paula O{\textquoteright}Connor and Monica Bojko and Amber Smith and Vasilios Vasilopoulos and Ruta Rao and Joy Sclamberg and Patricia Robinson",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = nov,

doi = "10.1007/s10549-021-06358-6",

language = "English",

volume = "190",

pages = "121--132",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

number = "1",

}

TY - JOUR

T1 - Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer

AU - Sheean, Patricia

AU - Gomez-Perez, Sandra

AU - Joyce, Cara

AU - O’Connor, Paula

AU - Bojko, Monica

AU - Smith, Amber

AU - Vasilopoulos, Vasilios

AU - Rao, Ruta

AU - Sclamberg, Joy

AU - Robinson, Patricia

PY - 2021/11

Y1 - 2021/11

KW - Epidemiology

KW - Metastatic breast cancer

KW - Myosteatosis

KW - Sarcopenia

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=85112364009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112364009&partnerID=8YFLogxK

U2 - 10.1007/s10549-021-06358-6

DO - 10.1007/s10549-021-06358-6

M3 - Article

C2 - 34389926

AN - SCOPUS:85112364009

SN - 0167-6806

VL - 190

SP - 121

EP - 132

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Cite this